Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer

Autor: Karel C, Smit, Jeroen W G, Derksen, Geerard L O, Beets, Eric J Th, Belt, Maaike, Berbée, Peter Paul L O, Coene, Hester, van Cruijsen, Marjan A, Davidis, Jan Willem T, Dekker, Joyce M, van Dodewaard-de Jong, Annebeth W, Haringhuizen, Helgi H, Helgason, Mathijs P, Hendriks, Ronald, Hoekstra, Ignace H J T, de Hingh, Jan N M, IJzermans, Johan J B, Janssen, Joop L M, Konsten, Maartje, Los, Leonie J M, Mekenkamp, Peter, Nieboer, Koen C M J, Peeters, Natascha A J B, Peters, Hans J F M, Pruijt, Patricia, Quarles van Ufford-Mannesse, Ron C, Rietbroek, Anandi H W, Schiphorst, Arjan, Schouten van der Velden, Ruud W M, Schrauwen, Mark P S, Sie, Dirkje W, Sommeijer, Dirk J A, Sonneveld, Hein B A C, Stockmann, Marleen, Tent, Frederiek, Terheggen, Manuel L R, Tjin-A-Ton, Liselot, Valkenburg-van Iersel, Ankie M T, van der Velden, Wouter J, Vles, Theo, van Voorthuizen, Johannes A, Wegdam, Johannes H W, de Wilt, Miriam, Koopman, Anne M, May, On Behalf Of The Plcrc Study Group

Publikováno v: Cancers; Volume 14; Issue 4; Pages: 1001
Cancers, 14(4):1001. Multidisciplinary Digital Publishing Institute (MDPI)
PLCRC study group 2022, ' Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer ', Cancers, vol. 14, no. 4, 1001 . https://doi.org/10.3390/cancers14041001
Cancers, 14
Cancers, 14, 4

Regular physical activity (PA) is associated with improved overall survival (OS) in stage I–III colorectal cancer (CRC) patients. This association is less defined in patients with metastatic CRC (mCRC). We therefore conducted a study in mCRC patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14b4aa9d6becdee85e39e2432df7d126
http://www.scopus.com/inward/record.url?scp=85125380998&partnerID=8YFLogxK

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Autor: Andrzej Piwowar, Fransje Aa Valster, Jeffrey P.B.M. Braak, Marije Ie Appels, Frits van Coevorden, Niels H Nielsen, Johanna E.A. Portielje, Jeroen Buijsen, Petra Flygare, Marije Slingerland, Nicole C.T. van Grieken, Jetske M. Meerum Terwogt, Maartje Los, Mattias Elmlund, Henk Boot, Rob L. H. Jansen, Johanna W. van Sandick, A. Haringhuizen, Johannes J. Bonenkamp, Harm van Tinteren, Edwin P.M. Jansen, Henk H. Hartgrink, Jaap De Boer, Anouk K. Trip, Ge Jpm Jonkers, Marie Louise Jespersen, Cecillia Lagerbäck, Per Edlund, Marco B Polée, Mats Perman, J (Hans)-Martin Mb Otten, Marjan A Van Dijk, Danny Houtsma, A (Bert) Jan Ten Tije, Arnold Baars, Olaf Jl Loosveld, Maud M. Geenen, Maarten C.C.M. Hulshof, Gerrit-Jan Veldhuis, Erik W Muller, Geert-Jan Creemers, Annelie Je Vulink, Quirijn A. J. Eijsbouts, Annerie Slot, Diane Grootenboers, Hein Putter, Ellen M Hendriksen, Maurice J.C. van der Sangen, Fabiënne A. R. M. Warmerdam, Tom Rozema, HA A. Maurits Swellengrebel, Henk K Van Halteren, Ate van der Gaast, Marcel Verheij, Richard Van Hilligersberg, Helene Hörberg, Pehr Lind, Annemieke Cats, Cornelis J.H. van de Velde, Jitty M Smit, Alex L. T. Imholz, Donald L. van der Peet, Aart Van Bochove, Henk M.W. Verheul, Adelheid Me Van der Torren-Conze, Frans L. G. Erdkamp, Dick Johan van Spronsen, Mark I. van Berge Henegouwen, Ernst Jan Spillenaar Bilgen, Johanna Mgh Van Riel, Marien O Den Boer, Hanneke W. M. van Laarhoven, Marjolein Em Rentinck, Ron C Rietbroek, Bengt Johansson, David Borg, Anders Johnsson, Aart Beeker, Reinoud J. B. Blaisse, Miriam Koopman, Daan Ten Bokkel Huinink, Karen J. Neelis, Elma Meershoek-Klein Kranenbarg, Djamila Boerma, Heleen M. Ceha, Bea C Tanis, Marie-Cecile Jc Legdeur, O Aart Van Dobbenburgh, Steven Vanhoutvin, Sjoerd Hovenga, Karolina Sikorska, Pètra M Braam, H Pieter van den Berg, Huub van der Mijle, Marianne Nordsmark, Bengt Glimelius

Publikováno v: lancet oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group

Item does not contain fulltext BACKGROUND: Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America. To our knowledge, these treatment strategies hav

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21019f3b155741c37a17771cdb957cb
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html